A Case of Postoperative Recurrence of Fibrolamellar Hepatocellular Carcinoma with Increased Vitamin B12 Binding Capacity in a Young Japanese Female

• Published in: Japanese journal of clinical oncology 2004-06, Vol.34 (6), p.346-351
• Main Authors: Kanai, Toshio, Takabayashi, Tsukasa, Kawano, Yukio, Kuramochi, Shigeru, Miyazawa, Naoto
• Format: Article
• Language: English
• Subjects: Adolescent; Carcinoma, Hepatocellular - diagnosis; Carcinoma, Hepatocellular - drug therapy; Carcinoma, Hepatocellular - pathology; Carcinoma, Hepatocellular - surgery; Hepatectomy; Humans; Key words: fibrolamellar hepatocellular carcinoma – vitamin B12 binding capacity – hepatectomy – multimodality treatment; Liver Neoplasms - diagnosis; Liver Neoplasms - drug therapy; Liver Neoplasms - pathology; Liver Neoplasms - surgery; Lymphatic Metastasis; Neoplasm Recurrence, Local; Postoperative Period; Tomography, X-Ray Computed; Transcobalamins - analysis
• ISSN: 0368-2811; 1465-3621
• DOI: 10.1093/jjco/hyh050

A 17-year-old Japanese female underwent major hepatic resection for a huge fibrolamellar hepatocellular carcinoma that was compressing the inferior vena cava. The tumor was not exposed at the surgical margin but was very close to it. A recurrent lesion at the surgical margin of the liver and a lymph node metastasis were discovered 9 months postoperatively together with a marked elevation of vitamin B12 binding capacity. These lesions were resected, and vitamin B12 binding capacity decreased thereafter. Peritoneal dissemination was detected by CT 16 months postoperatively, together with recurrent elevation of vitamin B12 binding capacity. Several types of chemotherapy, including intraperitoneal injection of epirubicin, were applied and improved the patient’s quality of life somewhat, but the patient died of recurrent disease 34 months after the initial hepatic resection. This is the first report in Japan of fibrolamellar hepatocellular carcinoma with increased vitamin B12 binding capacity as a useful marker. Fibrolamellar hepatocellular carcinomas, if resected, have a better prognosis than ordinary hepatocellular carcinoma in Japan, as well as in Western countries. An aggressive strategy should be chosen, which consists mainly of precise surgical resection and postoperative multimodality therapy, including chemotherapy.